Kaneka Corporation completed the acquisition of 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis.
April 04, 2018
Share
Kaneka Corporation (TSE:4118) signed an agreement to acquire 26.87% stake in AB-Biotics, S.A. (BME:ABB) from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis on March 28, 2018. Post transaction, founding partners Miquel Ángel Bonachera and Sergi Audivert will become shareholders with a joint stake of 20.22% while Chairman Luís Sánchez-Lafuente will be shareholder with 10.10%. Andrea Carreri, Giulia Cerutti and Gianluca de Cristofaro of Lega Colucci Morri & Associati and Gómez-Acebo & Pombo Abogados, S.L.P. acted as legal advisors to Kaneka Corporation.
Kaneka Corporation (TSE:4118) completed the acquisition of 26.87% stake in AB-Biotics, S.A. (BME:ABB) from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis on April 5, 2018.
AB-Biotics SA, also known as AB Biotics, is a Spain-based company engaged in the biotechnology industry business sector. It is dedicated to the research and development (R&D) of functional ingredients, drugs and tools for genetic analysis, as well as the nutraceutical and pharmaceutical industries. The Companyâs pipeline includes a range of supplements designed to improve health, from products that can lower the risk of cardiovascular disease to those that can help in the management of diabetes. It covers the development spectrum from marketed product, to proof-of-concept, and includes products that have been licensed to global food and pharmaceutical companies. The Company also provides outsourced R&D solutions to pharmaceutical companies, as well as functional food industry related companies. The Company offers different products, such as AB-Life, LipiGO, AB-Dentalac and AB-Colic, among others.
Kaneka Corporation completed the acquisition of 26.87% stake in AB-Biotics, S.A. from Corporacion Ivamosa, Gestion Y Administracion Mobiliaria, S.A., Capital MAB, FCR fund of Institut Català de Finances Capital, SGEIC, S.A. and Buanaventura Guamis.